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1. Introduction 
Osteoarthritis (OA) is described as a condition characterised by use-related joint pain 
experienced on most days in any given month, for which no other cause is apparent. OA is 
the commonest disease affecting synovial joints and affects more than 40% of the population 
over 65 years. It affects primary the knee joints however hip, ankle, shoulder and small 
joints of hand and feet may be involved. 
Previously, OA was considered a wear and tear, degenerative disease that must be accepted 
as an inevitable consequence of trauma and ageing. With advances in research and 
understanding of the mechanism of OA progression it is now known as a disease of the 
synovial joint affecting subchondral bone, synovium, meniscus, ligaments and supporting 
structures around the joints, including the cartilage. 
The pathological changes seen in OA are characterised by focal areas of loss of articular 
cartilage within the synovial joints, associated with hypertrophy of the bone (osteophytes 
and subchondral sclerosis) and thickening of the capsule. OA is a chronic, degenerative 
disease associated with joint pain and loss of function. The primary problem in OA is the 
damage to the articular cartilage, which triggers a series of other events that culminate in 
pain and loss/limitation of function in the affected joint. 
Undoubtedly, pain, which is the most prominent and disabling presentation of OA, is an 
increasingly important public health problem especially within an increasing aging 
population. 
2. Epidermiology 
OA occurs worldwide with higher prevalence in developed societies. Its twice as common in 
women as in men with a significant familial tendency. 
The prevalence of OA increases with age in a progressive manner with  80% radiolographic 
changes in people by the age of 65 years. However only about 25-30% are symptomatic. 
Primary OA is uncommon before the age of 50 years.  
World Health Organisation reports that knee OA is ranked fourth most important global 
cause of disability in women and the eighth most important in men. Annual arthroplasty 
rate in over the age of 65 in Europeans vary from country to country but are of the order of 
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0.5–0.7 per 1000. The annual costs attributable to knee OA are immense. There is therefore a 
burden on health from both morbidity and cost.  
OA is a complex disorder with multiple risk factors. 
2.1 Risk factors for OA  
1. Age > 50 years 
2. Crystals in joint fluid or cartilage 
3. High bone mineral density 
4. History of immobilisation 
5. Injury to the joint 
6. Joint hypermobility or instability 
7. Obesity (weight-bearing joints) 
8. Peripheral neuropathy 
9. Prolonged occupational or sports stress 
3 Anatomy of a joint 
A brief review of the basic anatomy of a typical synovial joint is presented here to help 
understand the mechanisms involved in OA-induced damages of the involved joint that 
culminate in pain and other symptoms of OA. 
 
 
Fig. 1. A typical synovial joint 
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A joint is where two bones meet. Articular cartilage covers the bone ends which are lubricated 
by synovial fluid. Seventy to eighty per cent of the cartilage is made up of water and a type II 
collagen with proteoglycans and glycosaminoglycans produced by chrondrocytes. The 
collagen fibres in the cartilage offer tensile strength to the cartilage because of its architectural 
makeup. The cartilage, however, contains no intrinsic blood vessels. It receives its nutrition 
from the synovial fluid. The synovial fluid, which is secreted by the synovial membrane lining 
the inner surface of the joint, facilitates not only movement but also provides nutrients, 
phagocytosis and other immunologic functions within the joint. The integrity of a joint is 
therefore dependent upon its architecture, the cartilage, bone and the supporting structures 
enclosing the joint. OA in simple terms is a result of alterations in the aforementioned 
architectural structures within the joint with resultant pain, loss of function and instability in 
the involved joint. Figure 1 shows the diagram of a typical synovial joint. 
4. Sources of nociception in a joint 
Pain is defined as “an unpleasant sensory and emotional experience associated with actual 
or potential tissue damage, or described in terms of such damage”. Pain, as generally 
acknowledged, is mainly a signal that the body has been injured. 
The term “nociception” was coined by the Nobel Laureate Sherrington to designate a 
physiological sensory phenomenon. “Nociception” is derived from “nocere”, the Latin word 
for “to hurt”. Nociceptors are peripheral sensory organs that are activated when nociceptive 
stimuli cause tissue damage. These nociceptors are unspecialised, naked nerve endings found 
close to small blood vessels and mast cells. The functional nociceptive unit is therefore made 
up of the structural triad of capillary, nociceptor and mast cell. This is the unit that is sensitive 
to tissue damage. There are also a rich supply of myelinated and unmyelinated fibres 
innervating the joint capsule, ligaments subchondral bone, periosteum and menisci.  
In the anatomy of the joint described above, the cartilage does not contain blood vessels but 
derives its nutrients from the synovium. The subchondral bone, periosteum, synovium, 
ligaments, and the joint capsule contain nerve endings that could be the source of 
nociceptive stimuli in OA. Irritation of the periostal as a result of remodelling, denuded 
bone, compression of soft tissue by osteophytes, microfractures of the subchondral bone, 
effusion and spasm of surrounding muscles has been shown to contribute to the pain that 
may be felt by patients with OA. So in effect the bone in the periosteum and bone marrow is 
richly innervated with nociceptive fibres and represents a potential source of nociceptive 
pain in patients with OA. 
5. Pathology and pathogenesis 
OA is a heterogenous spectrum of clinical condition affecting mostly joints. No one 
mechanism explains the various processes seen in the joint of OA. Factors including 
inflammation, genetic, injury or trauma and joint mechanics have all been implicated in the 
pathophysiology of OA. Each joint response is a balance of the anabolic and catabolic factors 
acting in combination with both the extrinsic and intrisic factors. 
Summary of the mechanisms suggested for the pathogenesis of OA are: 
• Matrix loss: Metalloproteinases (MMPs) such as stromelysin and collagenase which are 
secreted by the chondrocytes catalyses the degradation of both collagen and 
proteoglycans resulting in matrix loss 
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• Role of inflammatory mediators: Mediators such as TNF-α and IL-1 stimulate MMPs 
secretion and this inhibit collagen production. 
• Tissue inhibitors of MMPs: Tissue inhibitors of MMPs regulate the MMPs. Therefore any 
disturbance of this regulatory mechanism may lead to increased cartilage degradation 
and may contribute to the development of OA. 
• Growth factors deficiency: Growth factors such as insulin-like growth factor and 
transforming growth factor enhance collagen synthesis and so when these factors are 
deficient matrix repair is impaired. 
• Genetic susceptibility 
 
 
Fig. 2. Different factors that influence OA process. 
 
Stage I There is proteolytic breakdown of cartilage matrix
Stage II 
There is fibrillation and erosion of cartilage surface, accompanied by the release 
of breakdown products into the synovial fluid
Stage III 
Synovial inflammation begins when synovial cells ingest a breakdown product 
through phagocytosisand produce proteases and proinflammatory cytokines 
Table 1. Stages of OA (Martel-Pelletier, 2004) 




Has no known cause. Common. Related to aging and hereditary. 
 May be localised or generalised. Commonly affects the distal 
interphalangeal joints of the hands, hip and the knee. The cervical and  
lumbar spine may be affected.
Secondary  
OA 
Causes include articular injury, obesity, Paget’s disease, or inflammatory 
arthritis and aging process. May be localised or generalised. May affect any 
joint and can occur at any age. 
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5.2 Clinical features 
Pain and functional restriction are the main symptoms in OA. The pain is characteristically 
made worse by  movement and relieved by rest. 
 
Signs Symptoms 
Joint tenderness Joint pain 
Crepitus on movement 
Joint gelling (stiffening and pain after 
mobility) 
Limitation of range of movement Joint instability 
Joint instability Loss of function 
Joint effusion and variable levels of inflammation  
Bone swelling  
Wasting of muscles  
 
 
Fig. 3. Radiological changes in Osteoarthritis of the knees. (A) AP view of the left knee 
shows medial joint space narrowing (arrow). (B) Lateral view shows sclerosis with marked 
osteophyte formation (arrows). (C) Medial joint space narrowing (white arrow) causing a 
varus deformity of the knee and collapse of the joint space with destruction of the medial 
cartilage and the subchondral cortex (open arrow heads). (D) Subchondral cysts are noted 
(solid arrow head). 
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5.3 Radiological changes in OA 
• Joint space narrowing 
• Osteophytes 
• Bony cysts 
• Subchondral sclerosis 
5.4 Mechanism of pain in OA 
Summary of process of pain perception 
• A noxious stimulus causes stimulation of nociceptors (pain receptors) in the receptor 
organ (e.g. joint). 
• This firing of primary afferent fibres at the site of tissue injury causes axonal release 
of substance P (SP). This stimulation leads to activation of cells in the dorsal horn of 
the spinal cord and transmission of the nerve impulse to the midbrain and cortex. 
Thus, impulses travelling along first order neuron synapse on second-order neuron 
in the dorsal horn of the spinal cord. The axon crosses to the contralateral side and 
ascends to synapse on the third-order neurons. The third-order neurons send fibres 
to the cerebral cortex where conscious perception of the sensation occurs. 
• Transmission of sensory information is modulated (inhibited or potentiated) 
throughout the nervous system by neurons from the midbrain and spinal cord that 
release endogenous opioids, catecholamines and other neurotransmitters. 
• Peripheral nociceptor sensitisation, which is the transmission of impulses at 
subnormal threshold, occurs following the release of chemical mediators such as 
prostagladins and leukotrienes at the site of injury or damage. Continued stimulation 
by peripheral nociceptors then leads to sensitisation of neurons in the spinal cord. 
This is known as central sensitisation. 
Tissue injury results in the release of inflammatory mediators such as serotonin, bradykinin, 
calcitonin gene-related peptide (CGRP) and SP, which lead to nociceptor nerve fibre 
sensitisation in peripheral tissue. These damaged fibres release inflammatory agents causing 
a spread of increased sensitivity around the area of tissue damage. This is called primary 
hyperalgesia. The repeated depolarisation of primary afferent fibres leads to a continuous 
release of neurotransmitters onto the secondary neurons in the spinal cord, resulting in 
central sensitisation and secondary hyperalgesia. Peripheral pain sensitisation is a feature of 
osteoarthritis in the joint.  
In addition to peripheral pain sensitisation pain in OA, could also be due to local and central 
sensitisation of pain, pathways resulting in normal stimuli becoming painful with 
inflammation being an important feature in the process of OA. 
Most of the substances involved in inflammation such as proinflammatory cytokines and 
bradykinins interact with the nociceptive fibres present within the joint and induce 
hyperalgesia and allodynia seen in patients with chronic inflammatory joint disease like OA. 
These mechanisms acting in concert could participate in the progression of hyperalgesia to 
chronicity. 
5.5 Progression of OA to chronicity 
Chronic pain (CP) is pain that persists for a month beyond the usual course of an acute 
disease or a reasonable time period for an injury to heal. 
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CP differs from the acute process not only in the duration of its course but also the different 
receptors involved in the mechanisms of action for acute pain and CP. 
Those most involved in the acute process are a-amino-3-hydroxy- 5-methyl-isoxazole-4-
propionic acid (AMPA) receptors, while those of primary importance in the sensation of CP 
are N-methyl- D-aspartate (NMDA) receptors. Activation of NMDA receptors causes the 
release of peptide neurotransmitter SP, which amplifies the pain by causing the spinal 
neurons carrying the pain to be easily stimulated. 
Elevated levels of SP in spinal fluids have been documented in patients with OA and 
fibromyalgia. The progression of nociception from an acute to a chronic process has yet to be 
fully understood. However, recent evidence from animal experiments as well as human 
research suggests that peripheral mechanisms in acute pain and long-term potentiation 
(LTP) of neuronal sensitivity to nociceptive inputs in the dorsal horn of the spinal cord may 
underline the transition from acute to a chronic process. 
LTP in spinal nociceptive systems has been suggested as one of the mechanisms 
underpinning the transition of acute pain to CP. It seems possible that LTP may underlie 
some forms of afferent induced hyperalgesia and that simultaneous activation of NMDA; SP 
neurokinin-I (NK-I) and glutamate receptors are required for the induction of spinal LTP. 
Therefore, it is likely that the conditioning stimuli that induce synaptic LTP in the superficial 
spinal dorsal horn are similar to those that trigger hyperalgesia. LTP is likely to occur in 
both the sensory and the affective pain pathways. Additionally, spinal LTP and injury-
induced hyperalgesia share signal transduction pathways, which make use-dependent LTP 
an attractive model of injury-induced central sensitisation and hyperalgesia. 
Summary of progression to chronic pain state 
1. Rapid, intense stimulation of CA1 neurons in the hippocampus depolarizes them.  
2. Binding of Glu and D-serine to their NMDA receptors opens them.  
3. Ca2+ ions flow into the cell through the NMDA receptors and bind to calmodulin.  
4. This activates calcium-calmodulin-dependent kinase II (CaMKII).  
• CaMKII phosphorylates AMPA receptors making them more permeable to the 
inflow of Na+ ions and thus increasing the sensitivity of the cell to depolarization.  
• In time CaMKII also increases the number of AMPA receptors at the synapse. 
5. Increased gene expression (i.e., protein synthesis — perhaps of AMPA receptors) also 
occurs during the development of LTP.  
6. Enlargement of the synaptic connections and perhaps the formation of additional 
synapses occur during the formation of LTP.  
6. Treatment: emerging techniques and technologies  
The modes of treatment for OA have always focus on decreasing pain and improving 
function ranging from information, education, physical therapy and aids, through 
analgesics, non-steroidal anti-inflammatory drugs and joint injections, and to surgery in 
which all or part of the joint is replaced with plastic, metal or ceramic implants. 
OA is complex in genetics, pathogenesis, monitoring and treatment however, the principal 
goals of management are: 
• Education of the patient about OA 
• Pain relief  
• Achieving and maintaining optimal joint and limb function  
• Reducing adverse factors to beneficially modify the OA process and its outcome.  
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Despite huge laboratory and clinical research, there are no proven diseases modifying 
therapies for OA. However, emerging orthopaedic surgical procedures may help to alleviate 
the attendant pain and functional loss resulting from joint damage in OA. 
Some of the surgical approaches in the management of OA include 
• Arthroscopic approach 
• Osteotomies 
• Total joint replacements and arthrodesis 
• Tissue engineering and biologic therapies 
• Autologous Chondrocyte Implantation (ACI) 
• Meniscal Transplantation (MT) 
6.1 Arthroscopic procedures for OA 
Arthroscopic surgery is a routine surgical procedure for joint debridement and lavage in the 
management of OA since the 1980s.  The advent of this technique has permitted less invasive 
access to joints and the opportunity to intervene earlier in the course of joint destruction, 
potentially to delay and/or prevent a predictably progressive degenerative pathway.  
However, in recent times the only indication where this technique is thought to be of benefit is 
in the management of OA with a superimposed structural lesion such as a meniscal tear in 
which arthroscopic partial meniscectomy (APM) is performed simultaneously. 
There is a strong research and clinical evidence that patients with symptoms attributable to 
knee OA per se, and not meniscal tear, do not improve following arthroscopic lavage and 
debridement. Whether APM is useful in patients with symptomatic meniscal tear and 
concomitant OA is unclear at this stage. This is an area of investigation at the moment. 
6.2 Osteotomies 
Osteotomies are performed to restore a more anatomic biomechanical environment and 
prevent or delay the onset of OA or slow its progression. 
In symptomatic patients with OA, osteotomy is performed to realign joints with the aims of 
relieving pain and delaying the onset or progression of OA. Osteotomy and joint preserving 
surgical procedures should be considered in young adults with symptomatic OA, especially 
in the presence of dysplasia or varus/valgus deformity.  
6.2.1 Indications 
• As an adjunct in younger patients with predominantly unicompartmental OA  
• Age less than 60 years 
• 10 to 15 degrees of varus deformity on weight bearing radiographs 
• Preoperative motion arc of at least 90 degrees 
• Flexion contracture less than 15 degrees 
• Ability and motivation to effectively and safely perform rehabilitation 
6.2.2 Contraindications to osteotomy  
• Lateral compartment loss of joint space 
• Lateral tibial subluxation greater than 1 centimeter 
• Medial bone loss greater than 2 to 3 millimeters 
• Ligamentous instability 
• Inflammatory arthritis 
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6.3 Total joint replacements and arthrodesis 
Total joint replacement (TJR) has to be considered in patients with radiographic evidence of 
hip/ knee OA who have refractory pain and disability. Principally, OA occurs less commonly 
at ankle, elbow, and wrist and thus total joint replacements are less frequent at these sites than 
at the hip or knee. In the last few years, interest in total knee arthroplasty has resulted in a 
proliferation of prosthetic designs, and many different types are now aaialble.  
The indications for TJR have evolved and are expanding. Currently TJR are offered to 
patients earlier in the course of the disease as the risks of complications associated with TJR 
have reduced dramatically. 
The prostheses available are: 
1. Condvlar replacements: The joint surfaces alone are replaced. Ligaments then are needed 
to provide stability.    
2. Hinge-type prostheses: In this type the ligaments are sacrificed and stability is provided 
by the design of the prosthesis itself. 
The selection of a suitable prosthesis is dependent on the type and the indications 
Types of prostheses 
1. Unicondylar 
This is an anatomically designed replacement for either the medial or the lateral femoral 
tibial articulation. It is designed to allow 120 degrees of flexion. The unicondvlar prosthesis is 
used only for cornpartmental OA. 
2. Duocondylar 
The femoral component of the duocondylar prosthesis is similar in shape to that of the 
unicondylar model except that there is no anterior flange and instead the halves are 
connected by an anterior cross bar which is countersunk during insertion. Because of its 
anatomical shape, it is most suitable when deformity, instability, and flexion contracture are 
not too severe. 
3. Geometric 
The prosthesis is non-anatomical in that the curvature of the femoral component is of 
constant radius. The plastic tibial component is in one piece, with two halves connected by 
an anterior bar. The prosthesis is designed to allow a 90- degree arc of motion. The cruciate 
ligaments are preserved. Two sizes are available.  
4. Guepar 
The Guepar is a Vitallium hinge prosthesis (improved over the Young model) which is fully 
constrained, providing motion in a fixed axis without rotation. Guepar prosthesis was used 
in knees with extrerne deformity or instability due to rheumatoid arthritis and OA. 
Innovation continues to characterize the TJR field. This clinical dilemma has stimulated a 
search for biomaterials that produce less wear debris and, in turn, cause less osteolysis, 
attendant bone loss, and implant failure. This is the rationale for several developments, 
including highly cross-linked polyethylene and ceramic- on-ceramic and metal-on-metal 
bearing surfaces. 
6.4 Surgical and biologic procedures 
Advances in tissue engineering and biologic therapy have led to a few limited successes. 
Perhaps the most notable is autologous chondrocyte implantation (ACI).  
Indications 
1. Age <50 years 
2. Isolated cartilage defects typically greater than 3 cm2 in size 
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This procedure attempts to repair a symptomatic cartilage defect (Figure 3A) through 
implantation of chondrocytes grown ex vivo from a small cartilage biopsy sample 
obtained from the patient in a staging arthroscopy. After debridement of any degenerated 
tissue in the defect, a patch material, either periosteum from the patient or a synthetic 
collagen membrane, is sutured over the defect to create a watertight chamber into which 
the chondrocyte suspension is injected (Figure 3B). The chondrocytes attach to the 




Fig. 5. Total hip replacement 
6.5 Conclusion 
It is clear from the foregoing that any simple unitary concept about the link between joint 
damage and symptoms in OA is untenable. We are faced with a complex interaction 
between local events in the joint, pain sensitisation, the cortical experience of pain, and what 
people are doing in their everyday lives. 
In the absence of effective disease-modifying therapy, many patients with OA progress to 
advanced joint destruction. Therefore, surgery plays an important role in the management 
of OA. Advances in biomaterials and tissue engineering will continue to create exciting new 
opportunities to integrate surgical approaches in OA care.  
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Fig. 6. Total knee replacement 
 
 
Fig. 7. A, Cartilage defect on femoral condyle.  
B, Cartilage defect treated with autologous cartilage implantation 
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